Clinical Trial Update: Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II trial evaluating Velcade (bortezomib) plus Zevalin in relapsed or refractory follicular lymphoma has terminated with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Lymphoma

Drugs mentioned

• Velcade (bortezomib)
• Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: Northwestern University | Conditions: Lymphoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2018-10-17